|
UA73965C2
(en)
*
|
1999-12-08 |
2005-10-17 |
Theravance Inc |
b2 ADRENERGIC RECEPTOR ANTAGONISTS
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
TW200510277A
(en)
*
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
|
TW200526547A
(en)
*
|
2003-09-22 |
2005-08-16 |
Theravance Inc |
Amino-substituted ethylamino β2 adrenergic receptor agonists
|
|
TW200531692A
(en)
*
|
2004-01-12 |
2005-10-01 |
Theravance Inc |
Aryl aniline derivatives as β2 adrenergic receptor agonists
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
CA2561400A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
WO2006031556A2
(en)
*
|
2004-09-10 |
2006-03-23 |
Theravance. Inc. |
Amidine substituted aryl aniline compounds
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
WO2006051373A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Pfizer Limited |
Compounds for the treatment of diseases
|
|
WO2006066907A1
(en)
*
|
2004-12-21 |
2006-06-29 |
Glaxo Group Limited |
Pharmaceutical formulations
|
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP2540725A1
(de)
|
2006-05-04 |
2013-01-02 |
Boehringer Ingelheim International GmbH |
Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
EP2201018B1
(en)
*
|
2007-09-19 |
2016-03-16 |
Ambit Biosciences Corporation |
Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-ý7-(2-morpholin-4-yl-ethoxy)imidazoý2,1-b¨ý1,3¨benzothiazol-2-yl¨phenyl}urea, compositions thereof, and uses therewith
|
|
JP5325517B2
(ja)
*
|
2007-10-12 |
2013-10-23 |
住友化学株式会社 |
ジベンゾオキセピン化合物の精製方法
|
|
JP2009102249A
(ja)
*
|
2007-10-22 |
2009-05-14 |
Sumitomo Chemical Co Ltd |
ジベンゾオキセピン化合物の結晶の製造方法
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
CN102149407A
(zh)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
治疗糖尿病和相关病症的组合疗法
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
CN102256976A
(zh)
|
2008-12-23 |
2011-11-23 |
贝林格尔.英格海姆国际有限公司 |
有机化合物的盐形式
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
|
WO2011061527A1
(en)
|
2009-11-17 |
2011-05-26 |
Astrazeneca Ab |
Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
|
WO2011161161A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
|
GB201016912D0
(en)
|
2010-10-07 |
2010-11-24 |
Astrazeneca Ab |
Novel combination
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
US8883800B2
(en)
|
2011-07-15 |
2014-11-11 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
|
US8765725B2
(en)
|
2012-05-08 |
2014-07-01 |
Aciex Therapeutics, Inc. |
Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
|
|
EP2847207B1
(en)
|
2012-05-08 |
2019-03-27 |
Nicox Ophthalmics, Inc. |
Fluticasone propionate nanocrystals
|
|
JP6218811B2
(ja)
|
2012-05-14 |
2017-10-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
US9815865B2
(en)
|
2013-01-07 |
2017-11-14 |
Nicox Ophthalmics, Inc. |
Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
|